$FBRX
Forte Biosciences, Inc.

2021 Q3 Form 10-Q Financial Statement

#000156459021055083 Filed on November 08, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.043M $1.320M $760.0K
YoY Change 54.77% -65.63% -84.33%
% of Gross Profit
Research & Development $5.656M $3.688M $32.10M
YoY Change 53.36% 944.76% 168.17%
% of Gross Profit
Depreciation & Amortization $9.000K $10.00K $20.00K
YoY Change -10.0% -95.65% -90.48%
% of Gross Profit
Operating Expenses $7.699M $5.008M $32.10M
YoY Change 53.73% -70.77% 90.8%
Operating Profit -$7.699M
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$52.00K -$90.00K -$10.00K
YoY Change -42.22% 1400.0% -96.66%
Pretax Income -$7.751M -$5.100M -$34.76M
YoY Change 51.98% -72.78% 103.16%
Income Tax
% Of Pretax Income
Net Earnings -$7.751M -$5.100M -$34.76M
YoY Change 51.98% 639.13% 5417.62%
Net Earnings / Revenue
Basic Earnings Per Share -$0.54
Diluted Earnings Per Share -$544.3K -$455.0K -$9.523M
COMMON SHARES
Basic Shares Outstanding 14.24M 23.91M
Diluted Shares Outstanding 14.24M

Balance Sheet

Concept 2021 Q3 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $45.67M $20.20M $27.70M
YoY Change 126.06% -63.5% -59.46%
Cash & Equivalents $45.70M $20.20M $27.70M
Short-Term Investments
Other Short-Term Assets $891.0K $1.400M $400.0K
YoY Change -36.36% -66.67% -91.11%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $46.56M $21.60M $28.10M
YoY Change 115.54% -63.72% -61.4%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $110.0K $100.0K
YoY Change -100.0% -96.95% -97.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $834.0K $1.003M $0.00
YoY Change -16.85% 19960.0% -100.0%
Total Long-Term Assets $834.0K $1.130M $200.0K
YoY Change -26.19% -89.92% -98.39%
TOTAL ASSETS
Total Short-Term Assets $46.56M $21.60M $28.10M
Total Long-Term Assets $834.0K $1.130M $200.0K
Total Assets $47.39M $22.73M $28.30M
YoY Change 108.49% -67.87% -66.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.330M $1.513M $2.600M
YoY Change 54.0% -34.02% 3.96%
Accrued Expenses $1.410M $898.0K $866.0K
YoY Change 57.02% -92.26% -91.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.740M $2.411M $3.400M
YoY Change 55.12% -94.22% -80.36%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.740M $2.411M $3.400M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $3.740M $2.400M $3.400M
YoY Change 55.83% -95.29% -93.03%
SHAREHOLDERS EQUITY
Retained Earnings -$69.80M -$46.90M -$41.80M
YoY Change 48.83% -82.55% -83.29%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $43.65M $20.32M $24.88M
YoY Change
Total Liabilities & Shareholders Equity $47.39M $22.70M $28.30M
YoY Change 108.77% -67.91% -66.8%

Cashflow Statement

Concept 2021 Q3 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$7.751M -$5.100M -$34.76M
YoY Change 51.98% 639.13% 5417.62%
Depreciation, Depletion And Amortization $9.000K $10.00K $20.00K
YoY Change -10.0% -95.65% -90.48%
Cash From Operating Activities -$5.127M -$7.740M -$4.010M
YoY Change -33.76% -39.01% -77.92%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $3.580M
YoY Change -100.0% -1378.57%
Cash From Investing Activities $0.00 $0.00 $3.580M
YoY Change -100.0% -973.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.000K 160.0K 24.06M
YoY Change -101.88% 1500.0% 271.87%
NET CHANGE
Cash From Operating Activities -5.127M -7.740M -4.010M
Cash From Investing Activities 0.000 0.000 3.580M
Cash From Financing Activities -3.000K 160.0K 24.06M
Net Change In Cash -5.130M -7.580M 23.63M
YoY Change -32.32% -213.47% -295.29%
FREE CASH FLOW
Cash From Operating Activities -$5.127M -$7.740M -$4.010M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3D
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
834000
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M12D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M29D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y6M29D
us-gaap Net Income Loss
NetIncomeLoss
-18367000
us-gaap Net Income Loss
NetIncomeLoss
-41911000
fbrx Non Cash Research And Development In Process Acquired
NonCashResearchAndDevelopmentInProcessAcquired
30885000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-4769000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11209052
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
45000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
32057000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7699000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-5100000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2050000
CY2020Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
10515000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
43000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
24016000
CY2020Q2 fbrx Stock Issued During Period Value Reverse Merger
StockIssuedDuringPeriodValueReverseMerger
31809000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
47000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-34761000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
24878000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
166000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
375000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-5100000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
20319000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
495000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4804000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
54698000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5812000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
49909000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
19000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1473000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-7751000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
43650000
us-gaap Depreciation
Depreciation
36000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
61000
us-gaap Share Based Compensation
ShareBasedCompensation
401000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-718000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-394000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13095000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14620000
fbrx Cash And Restricted Cash Acquired In Reverse Merger
CashAndRestrictedCashAcquiredInReverseMerger
3582000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3582000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
24016000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
66000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
61000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
258000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24274000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13100000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13236000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58765000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6939000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45665000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20175000
fbrx Conversion Of Preferred Stock To Common Stock
ConversionOfPreferredStockToCommonStock
10515000
us-gaap Stock Issued1
StockIssued1
31809000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
40000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
297000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-69800000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13100000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45700000
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
61000
CY2021Q3 fbrx Transfers Between Fair Value Hierarchy Levels
TransfersBetweenFairValueHierarchyLevels
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:3.78%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. Significant management estimates that affect the reported amounts of assets and liabilities include useful lives of property and equipment, stock-based compensation, accruals for clinical trials and drug manufacturing and deferred tax assets. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. </span></p>
CY2020Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
32100000
CY2021Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
61000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1528690
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3815476
CY2021Q3 fbrx Prepaid Manufacturing And Clinical Expenses
PrepaidManufacturingAndClinicalExpenses
243000
CY2020Q4 fbrx Prepaid Manufacturing And Clinical Expenses
PrepaidManufacturingAndClinicalExpenses
488000
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
504000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
395000
CY2021Q3 fbrx Prepaid License
PrepaidLicense
25000
CY2020Q4 fbrx Prepaid License
PrepaidLicense
100000
CY2020Q4 us-gaap Prepaid Taxes
PrepaidTaxes
74000
CY2021Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
119000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
76000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
891000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1133000
CY2021Q3 fbrx Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
715000
CY2020Q4 fbrx Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
861000
CY2021Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
106000
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
289000
CY2020Q4 fbrx Deposits For Manufacturing Components
DepositsForManufacturingComponents
82000
CY2021Q3 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
13000
CY2020Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
12000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
834000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1244000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
69000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
86000
CY2021Q3 fbrx Accrued Manufacturing And Clinical Expenses
AccruedManufacturingAndClinicalExpenses
513000
CY2020Q4 fbrx Accrued Manufacturing And Clinical Expenses
AccruedManufacturingAndClinicalExpenses
237000
CY2021Q3 fbrx Accrued Compensation
AccruedCompensation
767000
CY2020Q4 fbrx Accrued Compensation
AccruedCompensation
646000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
61000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
50000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1410000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1019000
CY2021Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2021Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P6M
CY2021Q3 fbrx Operating Lease Revenue Or Expense
OperatingLeaseRevenueOrExpense
9000
us-gaap Operating Lease Expense
OperatingLeaseExpense
0
fbrx Rent Credit Due To Refund For Operating Expense Adjustments
RentCreditDueToRefundForOperatingExpenseAdjustments
9000
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
5000
us-gaap Operating Lease Expense
OperatingLeaseExpense
19000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.49
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
21.89
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.34
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.30
CY2021Q3 fbrx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Of Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsOfCommonStock
30.63
CY2020Q3 fbrx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Of Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsOfCommonStock
21.64
fbrx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Of Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsOfCommonStock
35.78
fbrx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Of Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsOfCommonStock
16.79
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0091
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0036
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0094
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0049
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.672
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.700
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.690
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.700
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
14300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y18D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1123496
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.72
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
27800000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
566500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
35.78
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
29575
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
366000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
151165
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
24.09
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1509256
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.70
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1036000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
200181
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
18.13
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
53000
fbrx Share Based Compensation Arrangement By Share Based Payment Award Options Fair Value Of Stock Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueOfStockPrice
2.96
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1473000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
375000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2976000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
401000

Files In Submission

Name View Source Status
0001564590-21-055083-index-headers.html Edgar Link pending
0001564590-21-055083-index.html Edgar Link pending
0001564590-21-055083.txt Edgar Link pending
0001564590-21-055083-xbrl.zip Edgar Link pending
fbrx-10q_20210930.htm Edgar Link pending
fbrx-10q_20210930_htm.xml Edgar Link completed
fbrx-20210930.xsd Edgar Link pending
fbrx-20210930_cal.xml Edgar Link unprocessable
fbrx-20210930_def.xml Edgar Link unprocessable
fbrx-20210930_lab.xml Edgar Link unprocessable
fbrx-20210930_pre.xml Edgar Link unprocessable
fbrx-ex311_7.htm Edgar Link pending
fbrx-ex312_8.htm Edgar Link pending
fbrx-ex321_9.htm Edgar Link pending
fbrx-ex322_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending